How Insurers Attempt to Discourage Biologic Therapy for Psoriasis

Autor:	Madelaine Haddican, Darrell S. Rigel, Russell D. Rutter
Rok vydání:	2013
Předmět:	medicine.medical_specialty business.industry General Arts and Humanities Psoriasis Medicine business Intensive care medicine medicine.disease
Zdroj:	Psoriasis Forum. :114-116
ISSN:	1557-3168 1089-3504
DOI:	10.1177/247553031319a00306
Popis:	Background Biologic therapy for psoriasis is costly, and insurance companies vary in the pre-authorization procedures required for these treatments. Methods A survey was performed of more than 300 of the approximately 600 practicing dermatologists at the Fall Clinical Dermatology Conference. Results More than 80% of those surveyed prescribe biologic therapies for psoriasis. Sixty percent have to obtain prior authorizations more than 80% of the time before prescribing biologics. For many patients, prior authorizations have to be repeated every three months. The median amount of time spent on prior authorizations was between 30 and 60 minutes and 50% of dermatologists require at least one-quarter of a full-time employee to deal with the paperwork. Eighty percent of dermatologists thought that reimbursement hurdles prevent them from using ideal therapies for psoriasis. Conclusion The paperwork associated with prescribing biologic agents generates unreimbursed expenses and may interfere with ideal treatments for patients with psoriasis.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4bcedb60411886405db7b9a82e8ea6f0 https://doi.org/10.1177/247553031319a00306 Zobrazit plný text záznamu